Yantai

This research aims to evaluate the effectiveness of Mosapride Citrate Injection in treating postoperative gastrointestinal dysfunction. The study is a multicenter, randomized, double-blind, parallel, placebo-controlled phase II clinical trial involving adult patients undergoing certain types of intestinal surgery. It seeks to understand how this treatment influences recovery after surgery, focusing on gastrointestinal function. Participants are randomly assigned to one of three groups one receiving a low dose of Mosapride Citrate Injection 4 mg, another receiving a high dose 8 mg, and a placebo group. Each treatment is given intravenously twice daily for 3 to 5 days. The study has three phases a screening period up to 28 days before surgery, a treatment period lasting 3 to 5 days after surgery, and a follow-up period of 7 days after the last dose. During the study, participants will be monitored for the time it takes to first pass gas after surgery, which indicates gastrointestinal recovery. Assessments include medical evaluations during screening, treatment monitoring, and follow-up visits. Safety and response to the medication are tracked throughout the study, which concludes approximately 7 days after treatment ends.